Squarepoint Ops LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 9,823 shares of the company’s stock, valued at approximately $340,000.
A number of other large investors have also recently bought and sold shares of PTGX. GSA Capital Partners LLP grew its position in shares of Protagonist Therapeutics by 179.8% in the first quarter. GSA Capital Partners LLP now owns 55,359 shares of the company’s stock valued at $1,602,000 after purchasing an additional 35,571 shares during the last quarter. Vanguard Group Inc. grew its position in Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares in the last quarter. Seven Eight Capital LP grew its position in Protagonist Therapeutics by 426.9% during the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after buying an additional 29,810 shares in the last quarter. Bank of New York Mellon Corp grew its position in Protagonist Therapeutics by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock worth $7,079,000 after buying an additional 17,065 shares in the last quarter. Finally, Opaleye Management Inc. acquired a new stake in Protagonist Therapeutics during the fourth quarter worth about $2,584,000. 98.63% of the stock is currently owned by institutional investors.
Insider Activity at Protagonist Therapeutics
In related news, CFO Asif Ali sold 14,203 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the transaction, the chief financial officer now owns 34,960 shares of the company’s stock, valued at $1,555,370.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Asif Ali sold 14,203 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the sale, the chief financial officer now directly owns 34,960 shares in the company, valued at $1,555,370.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $40.00, for a total value of $320,000.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at $480,000. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,203 shares of company stock valued at $1,311,891 in the last quarter. Insiders own 5.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Protagonist Therapeutics
Protagonist Therapeutics Stock Performance
Shares of PTGX opened at $43.59 on Friday. The firm’s 50-day simple moving average is $42.62 and its 200 day simple moving average is $35.13. Protagonist Therapeutics, Inc. has a 52 week low of $13.72 and a 52 week high of $48.00. The firm has a market cap of $2.56 billion, a P/E ratio of 17.86 and a beta of 2.17.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $4.17 million for the quarter, compared to analyst estimates of $40.00 million. As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current year.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a Death Cross in Stocks?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.